Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Circulating Fibroblast Activation Protein (FAP) As A Marker for Fibroblast-Driven Pathology in Rheumatoid Arthritis and Systemic Sclerosis : Implication for Joint, Skin and Lung Fibrosis

NCT07393217 is registered in ClinicalTrials.gov with Sohag University as lead sponsor.

NCT NCT07393217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07393217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Circulating Fibroblast Activation Protein (FAP) As A Marker for Fibroblast-Driven Pathology in Rheumatoid Arthritis and Systemic Sclerosis : Implication for Joint, Skin and Lung Fibrosis
Lead sponsor
Sohag University
Phase
Observational
Overall status
Not yet recruiting
Start date
March 1, 2026
Completion date
September 30, 2027
Enrollment
111 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis (ra), systemic sclerosis (ssc)